Loading stock data…
PTGX
$105.87+7.84 (+8.00%)
After Hours$105.87+0.00 (+0.00%)· Last close Jun 9
Protagonist Therapeutics, Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Protagonist Therapeutics, Inc. in the Healthcare sector is trading at $105.87. Wall Street consensus targets $118.69 (13 analysts), implying a +12.1% move over the next 12 months. The stock is currently near its 52-week high of $107.84, remaining 23.6% above its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the distress zone. The Whystock Score of 80/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +12.1% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Anchored to each ticker's own 5-year median trailing P/E, tilted by current ROE and growth. Fair P/E = own median P/E + (ROE × 10) + (max(revenue growth, earnings growth) × 15), capped at ±30% around the historical anchor. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. Premium compounders like COST/MSFT are judged against their own multi-year norm rather than a sector median. Falls back to the sector-anchored formula (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) for recent IPOs and tickers with insufficient history (< 24 monthly samples). Result is a normalised multiple gauge — not a price target.
Current Price$105.87
Potential Downside
0%
Whystock Fair Value$105.87
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus13 analysts
Mean target$118.69+12.1%
Range$100.00 – $137.00
Fundamentals
Protagonist Therapeutics, Inc. operates as a discovery and development company in the United States. It develops Icotyde, a first-in-class investigational targeted oral peptide for the treatment of adults and pediatric patients 12 years of age and ol...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
-
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-17.50%
Volume
Today's trading volume
861,847
Recent News
Why This Fund Made a $189 Million Bet on Erasca as Shares Skyrocket 800%
This clinical-stage biotech develops targeted oral therapies for RAS/MAPK-driven cancers, with all assets currently in development.
Tango Therapeutics Stock Is Up 840%, and This Fund Just Disclosed Buying $164 Million More
This biotechnology firm advances targeted cancer therapies, leveraging genetic insights and strategic partnerships in oncology.
J&J Mastered Cancer Biotech Deals on the Cheap. Can It Stay on the Cutting Edge?
Johnson & Johnson seems to have perfected the art of the biotech deal. Rather than spending billions on acquisitions, it has built much of its pharma empire through partnerships that capture huge upside for bargain prices. A biotech partnership is a bit like an open relationship: Your partner can always fall in love with someone else.
Hedge Fund Wagers $36 Million on Biotech Denali After First FDA Approval
This biotech develops therapies for neurodegenerative diseases, advancing a broad pipeline through strategic pharmaceutical partnerships.
Hedge Fund Drops $40 Million on Gene-Editing Biotech Beam. Is It a Buy?
Beam Therapeutics develops precision genetic medicines using base editing technology to target serious inherited diseases.